Table 1.
Table of participant characteristics.
| Participant characteristic | First 64mT Scan n = 87 |
|---|---|
| Gestation at birth [Weeks+days] | 38+2 (33+3–39+1) |
| Weight at birth [kg] | 2.92 (2.03–3.45) |
| Age at scan [Days] | 9 (4–36) |
| PMA at scan [Weeks+days] | 39+6 (37+4–40+6) |
| Weight at scan [kg] | 3.03 (2.45–3.45) |
| Sex | |
| Female (%) | 33 (38) |
| Male (%) | 54 (62) |
| Medical support during scan | |
| Mechanical ventilation (%) | 7 (8) |
| CPAP (%) | 1 (1) |
| LFNC (%) | 9 (10) |
| Prostaglandin infusion (%) | 8 (9) |
| Temperature controlled mattress (%) | 19 (22) |
| Inotropic therapy (%) | 2 (2) |
| Arterial line (%) | 2 (2) |
| Given chloral hydrate sedationa for 3T MR scan (%) | 29 (33) |
| 3T scan indication | |
| Clinical | 59 (68) |
| Infants without suspected neurological abnormality | 28 (32) |
| Co-morbidity | |
| Born preterm (%) | 30 (34) |
| Congenital cardiac lesions (%) | 23 (26) |
| Encephalopathy, abnormal movements/seizures or suspected HIE (%) | 17 (20) |
| Suspected developmental brain abnormalities (%) | 10 (11) |
| Suspected metabolic disorder (%) | 2 (2) |
| Post-meningitis (%) | 1 (1) |
| Post-ECMO (%) | 1 (1) |
| Focus of sequence development | |
| Solely T1 weighted sequence development (%) | 44 (51) |
| Solely T2 weighted sequence development (%) | 9 (10) |
| T1 & T2 weighted sequence development (%) | 34 (39) |
Continuous data are shown as: Median (Interquartile range).
PMA: post-menstrual age; CPAP: continuous positive airway pressure; LFNC: low flow nasal cannulae (Oxygen); HIE: hypoxic ischaemic encephalopathy; ECMO: extra-corporeal membrane oxygenation.
a
No infants without suspected neurological abnormality received chloral hydrate in this cohort.